Payless Compounders Recalls Compounded Semaglutide Injectable for "Lack of Assurance of Sterility"
FDA’s enforcement listings show a Class II recall (D-0471-2026) by Payless Compounders, LLC of Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg and 5 mg (1 mg/mL), in 0.5 mL prescription-only vials. The stated reason is "Lack of Assurance of Sterility." The recall is dated April 22, 2026 and its status is listed as ongoing.
What this meansSterility problems are invisible to the person holding the vial — recalls like this are why it matters to know exactly which pharmacy compounds your prescription and to check its recall history.
Source: FDA original ↗